Effects of incremental peritoneal dialysis with low glucose-degradation product neutral pH solution on clinical outcomes.
Incremental peritoneal dialysis
Peritoneal glucose exposure
Residual kidney function
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
06
03
2024
accepted:
06
05
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
Incremental peritoneal dialysis (IPD) could decrease unfavorable glucose exposure results and preserve (RKF). However, there is no standardization of dialysis prescriptions for patients undergoing IPD. We designed a prospective observational multi-center study with a standardized IPD prescription to evaluate the effect of IPD on RKF, metabolic alterations, blood pressure control, and adverse outcomes. All patients used low GDP product (GDP) neutral pH solutions in both the incremental continuous ambulatory peritoneal dialysis (ICAPD) group and the retrospective standard PD (sPD) group. IPD patients started treatment with three daily exchanges five days a week. Control-group patients performed four changes per day, seven days a week. A total of 94 patients (47 IPD and 47 sPD) were included in this study. The small-solute clearance and mean blood pressures were similar between both groups during follow-up. The weekly mean glucose exposure was significantly higher in sPD group than IPD during the follow-up (p < 0.001). The patients with sPD required more phosphate-binding medications compared to the IPD group (p = 0.05). The rates of peritonitis, tunnel infection, and hospitalization frequencies were similar between groups. Patients in the sPD group experienced more episodes of hypervolemia compared to the IPD group (p = 0.007). The slope in RKF in the 6th month was significantly higher in the sPD group compared to the IPD group (65% vs. 95%, p = 0.001). IPD could be a rational dialysis method and provide non-inferior dialysis adequacy compared to full-dose PD. This regimen may contribute to preserving RKF for a longer period.
Identifiants
pubmed: 38740705
doi: 10.1007/s11255-024-04077-7
pii: 10.1007/s11255-024-04077-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR (1997) Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 8:965–971
doi: 10.1681/ASN.V86965
pubmed: 9189865
Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, Group MNCS (2002) Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307–1320
doi: 10.1681/ASN.V1351307
pubmed: 11961019
Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT (2003) The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41:1293–1302
doi: 10.1016/S0272-6386(03)00362-7
pubmed: 12776283
Fernandes A, Matias P, Branco P (2023) Incremental peritoneal dialysis—definition, prescription, and clinical outcomes. Kidney360 4:272–277
doi: 10.34067/KID.0006902022
pubmed: 36821618
Golper T, Churchill D, Burkart J, Firanek C, Geary D, Gotch F, Moore L, Nolph K, Powe N, Singh H (1997) NKF DOQI clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 30:S67-136
doi: 10.1016/S0272-6386(97)70028-3
Dhoot A, Brown EA, Robinson B, Perl J (2023) Incremental peritoneal dialysis: incremental gains. SAGE Publications, London, pp 355–358
Brown EA, Blake PG, Boudville N, Davies S, de Arteaga J, Dong J, Finkelstein F, Foo M, Hurst H, Johnson DW (2020) International society for peritoneal dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis. Perit Dial Int 40:244–253
doi: 10.1177/0896860819895364
pubmed: 32063219
Cheetham MS, Cho Y, Krishnasamy R, Jain AK, Boudville N, Johnson DW, Huang LL (2022) Incremental versus standard (full-dose) peritoneal dialysis. Kidney Int Rep 7:165–176
doi: 10.1016/j.ekir.2021.11.019
pubmed: 35155856
Auguste BL, Bargman JM (2018) Incremental peritoneal dialysis: new ideas about an old approach. Semin Dial 31:445–448
doi: 10.1111/sdi.12712
pubmed: 29806970
Nolph KO, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP (1987) Peritoneal equilibration test. Perit Dial Int 7:138–148
doi: 10.1177/089686088700700306
Li PKT, Chow KM, Cho Y et al (2022) ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 42(2):110–153
doi: 10.1177/08968608221080586
pubmed: 35264029
Hayat A, Cho Y, Hawley CM, Htay H, Krishnasamy R, Pascoe E, Teitelbaum I, Varnfield M, Johnson DW (2023) Association of incremental peritoneal dialysis with residual kidney function decline in patients on peritoneal dialysis: the balANZ trial. Perit Dial Int. https://doi.org/10.1177/08968608231175826
doi: 10.1177/08968608231175826
pubmed: 37259236
Cheetham MS, Cho Y, Krishnasamy R, Milanzi E, Chow J, Hawley C, Moodie J-A, Jose MD, MacGinley R, Nguyen T (2023) Multicentre registry analysis of incremental peritoneal dialysis incidence and associations with patient outcomes. Perit Dial Int 43:383–394
doi: 10.1177/08968608231195517
pubmed: 37674306
Sandrini M, Vizzardi V, Valerio F, Ravera S, Manili L, Zubani R, Lucca BJ, Cancarini G (2016) Incremental peritoneal dialysis: a 10 year single-centre experience. J Nephrol 29:871–879
doi: 10.1007/s40620-016-0344-z
pubmed: 27582136
pmcid: 5080315
Tomo T, Okabe E, Matsuyama K, Iwashita T, Yufu K, Nasu M (2005) The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model. J Artif Organs 8:125–129
doi: 10.1007/s10047-005-0290-3
pubmed: 16094518
Ueda A, Nagai K, Yamagata K (2021) Preserved peritoneal function by short-term two-day peritoneal rest in hemodialysis combination therapy patients. J Artif Organs 24:296–300
doi: 10.1007/s10047-020-01215-7
pubmed: 33011888
Alrowiyti IM, Bargman J (2023) A review of residual kidney function in peritoneal dialysis patients. Indian J Nephrol 33:239–246
doi: 10.4103/ijn.ijn_242_23
pubmed: 37781547
pmcid: 10503572
Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG (2001) Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transpl 16:2207–2213
doi: 10.1093/ndt/16.11.2207
Wang AY-M, Wang M, Woo J, Lam CW-K, Lui S-F, Li PK-T, Sanderson JE (2004) Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15:2186–2194
doi: 10.1097/01.ASN.0000135053.98172.D6
pubmed: 15284304
Rhee H, Yang JY, Jung WJ, Shin MJ, Yang BY, Song SH, Kwak IS, Seong EY (2014) Significance of residual renal function for phosphate control in chronic hemodialysis patients. Kidney Res Clin Pract 33:58–64
doi: 10.1016/j.krcp.2014.01.001
pubmed: 26885471
pmcid: 4714245